❌

Normal view

There are new articles available, click to refresh the page.
Yesterday — 25 June 2024Main stream

When Sick Pets Need Blood, Animal ‘Superheroes’ Come to the Rescue

✇NYT: Science
By: Emily Anthes
25 June 2024 at 05:00
Transfusions have become an important part of veterinary medicine, but cat and dog blood is not always easy to come by.

© Michael Hanson for The New York Times

Jolie, a blood donor, giving blood at a DoveLewis Blood Bank in Portland, Ore., last month.
Before yesterdayMain stream

At Animal Hospitals, Social Workers Offer Care for the Humans

✇NYT: Science
By: Katie Thomas and Jamie Kelter Davis
24 June 2024 at 09:16
Though still rare, social workers in animal hospitals are growing in their ranks.

Claire Johnson, a veterinary social worker, left, comforted Zorro, a 16-year-old cockapoo, as he was prepared for euthanasia at MedVet, a 24-hour pet care facility in Chicago.

How Pet Care Became a Big Business

✇NYT: Technology
By: Katie Thomas
24 June 2024 at 09:31
People have grown more attached to their pets — and more willing to spend money on them — turning animal medicine into a high-tech industry worth billions.

© Audra Melton for The New York Times

Heather Massey of Carlton, Ga., with her dog, Lunabear. She is still paying off a bill for scans and care six years after her previous dog, Ladybird, was diagnosed with brain cancer.

How Pet Care Became a Big Business

✇NYT: Science
By: Katie Thomas
24 June 2024 at 09:31
People have grown more attached to their pets — and more willing to spend money on them — turning animal medicine into a high-tech industry worth billions.

© Audra Melton for The New York Times

Heather Massey of Carlton, Ga., with her dog, Lunabear. She is still paying off a bill for scans and care six years after her previous dog, Ladybird, was diagnosed with brain cancer.

Gilead's Twice-Yearly Shot to Prevent HIV Succeeds in Late-Stage Trial

✇Slashdot
By: EditorDavid
22 June 2024 at 12:34
An anonymous reader shared this report from CNBC: Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. None of the roughly 2,000 women in the trial who received the lenacapavir shot had contracted HIV by an interim analysis, prompting the independent data monitoring committee to recommend Gilead unblind the Phase 3 trial and offer the treatment to everyone in the study. Other participants had received standard daily pills. The company expects to share more data by early next year, the article adds, and if its results are positive, the company could bring its drug to the market as soon as late 2025. (By Fridayt the company's stock price had risen nearly 12%.) There's already other HIV-preventing options, the article points out, but they're taken by "only a little more than one-third of people in the U.S. who could benefit...according to data from the Centers for Disease Control and Prevention." Part of the problem? "Daily pills dominate the market, but drugmakers are now focusing on developing longer-acting shots... Health policymakers and advocates hope longer-acting options could reach people who can't or don't want to take a daily pill and better prevent the spread of a virus that caused about 1 million new infections globally in 2022."

Read more of this story at Slashdot.

Are We Loving Our Pets to Death?

✇NYT: Science
By: Linda Baker
22 June 2024 at 05:00
Pet owners are treating their animal charges ever more like humans. But that isn’t good for pets, or for us, many experts argue.

© Graham Dickie/The New York Times

The proliferation of dog strollers is one sign of a trend in which pets’ lives have become constrained and dependent on humans.

Researchers Still Fighting For MDMA Therapy After FDA Advisors Vote Against It

✇Slashdot
By: BeauHD
20 June 2024 at 23:30
An anonymous reader quotes a report from the BBC: A vote against using MDMA as part of therapy for PTSD has provoked a powerful backlash among researchers who study psychedelic drugs. Some 13 million Americans struggle with post-traumatic stress disorder (PTSD). Existing therapies only bring relief for a fraction of patients, and new treatments are sorely needed, according to psychiatrists wrestling with the scale of the problem. So, there was distinct disappointment when an advisory committee at the US Food and Drug Administration (FDA) voted earlier this month against a therapy that many had hoped could offer the first new treatment for PTSD in 25 years. A number of experts who study psychedelics have since spoken out in support of MDMA-assisted therapy for PTSD and have sharply criticized the recommendations of the FDA's Psychopharmacological Drugs Advisory Committee. But some are still optimistic that the treatment might be approved when the FDA delivers its final decision in August. While MDMA, also commonly known as ecstasy or molly, is listed as a Schedule 1 controlled substance in the US and so is illegal to use outside research, there has been a growing number of studies suggesting that when used with psychotherapy it could have potential for treating PTSD and some other mental health conditions. Ahead of the meeting, FDA approval of MDMA-assisted therapy for PTSD seemed likely, says Sandeep Nayak, an assistant professor of psychiatry at Johns Hopkins University, who investigates psychedelics as treatments for substance use and mood disorders. About two-thirds of people who received three sessions of MDMA and talk therapy no longer qualified for a PTSD diagnosis at the end of two Phase 3 clinical trials. It's an outcome that is "almost double that of existing medications", says Gul Dolen, a neuroscientist at the University of California, Berkeley, who researches the mechanisms of how psychedelics achieve therapeutic effects. "What's more, [the treatment] led to durable improvements in these patients lasting at least six months." About half of people who enroll in current gold standard PTSD treatments drop out, which is "absurd," says Loree Sutton, a psychiatrist and retired Brigadier General in the US Army. She says new treatments are essential. "We have to do better." "Even if there are risks, we've got to figure this out, because we cannot not let this treatment be available," adds Rachel Yehuda, a professor of psychiatry and neuroscience at the Icahn School of Medicine at Mount Sinai who has conducted studies on the effects of MDMA-assisted therapy for PTSD. "Without it, we're just leaving too many people in suffering that they don't need to be in, and that is not right." The FDA is currently considering an application from California-based drug company Lykos Therapeutics for using MDMA capsules taken in conjunction with therapy in the treatment of PTSD. In the recent FDA advisory meeting, committee members cited apparent flaws in study design and data collection. The nine-hour hearing concluded with committee members voting 9-2 that the available data do not show "that the drug is effective" for PTSD, and voting 10-1 that the benefits of MDMA do not outweigh the risks.

Read more of this story at Slashdot.

Many stunt performers are reluctant to report head injuries, study finds

✇Ars Technica
By: Jennifer Ouellette
17 June 2024 at 18:53
Ryan Gosling in <em>The Fall Guy</em>.

Enlarge / Ryan Gosling in The Fall Guy. (credit: Universal Pictures)

Ryan Gosling plays a Hollywood stuntman in the new action comedy The Fall Guy, a loose adaptation of the popular 1980s TV series of the same name starring Lee Majors. Gosling even did a few of his own stunts, although professional stunt performers handled the most dangerous sequences. It's their job to assume the risk so the stars don't get injured but that can translate into a high rate of head injuries in particular. According to a study published in the Journal of Occupational Medicine and Toxicology, a significant fraction of stunt performers never report such injuries, largely because it's a competitive industry, and they are afraid of losing work. The impacts can lead to more serious cognitive issues later in life.

“Many stunt performers are afraid to report their injuries, especially head trauma, in fear they will be put on a do-not-hire list or looked at as a liability,” said co-author Jeffrey Russell of Ohio University. “The more injuries or trauma, the harder it may be to find work. But that should not be how it is; production companies and their unions should be ensuring stunt performers are taken care of and not reprimanded for any injuries sustained on the job.”

The work builds on Russell's prior research, published last year, looking at the prevalence of head trauma and concussion in stunt performers and how well such injuries are managed. The prevalence of such injuries means that stunt performers are at high risk for chronic traumatic encephalopathy (CTE)—a degenerative brain disease associated with a history of repetitive head impacts that is a cause of much concern in collision sports like football and ice hockey—over the course of their careers.

Read 12 remaining paragraphs | Comments

The basic urge is surprisingly complex

✇MetaFilter
By: chavenet
16 June 2024 at 16:19
To most people, pulling into a highway rest stop is a profoundly mundane experience. But not to neuroscientist Rita Valentino, who has studied how the brain senses, interprets and acts on the bladder's signals. She's fascinated by the brain's ability to take in sensations from the bladder, combine them with signals from outside of the body, like the sights and sounds of the road, then use that information to act—in this scenario, to find a safe, socially appropriate place to pee. "To me, it's really an example of one of the beautiful things that the brain does," she says. from How Do We Know When to Pee? [Smithsonian; ungated]

Security Lessons from the Change Healthcare Ransomware Catastrophe

✇Slashdot
By: EditorDavid
15 June 2024 at 18:34
The $22 million paid by Change Healthcare's parent company to unlock its systems "may have emboldened bad actors to further target the vulnerable industry," writes Axios: There were 44 attacks against the health care sector in April, the most that [cybersecurity firm] Recorded Future has seen in the four years it's been collecting data. It was also the second-largest month-over-month jump, after 30 ransomware attacks were recorded in March. There were 32 attacks in February and May. But an analysis by the security-focused magazine CSO says the "disastrous" incident also "starkly illustrated the fragility of the healthcare sector, prompting calls for regulatory action." In response to the attack, US politicians have called for mandated baseline cybersecurity standards in the health sector, as well as better information sharing. They have also raised concerns that industry consolidation is increasing cyber risk. So what went wrong? The attackers used a set of stolen credentials to remotely access the company's systems. But the article also notes Change Healthcare's systems "suffered from a lack of segmentation, which enables easy lateral movement of the attack" — and that the company's acquisition may have played a role: Mergers and acquisitions create new cyber threats because they involve the integration of systems, data, and processes from different organizations, each with its own security protocols and potential vulnerabilities. "During this transition, cybercriminals can exploit discrepancies in security measures, gaps in IT governance, and the increased complexity of managing merged IT environments," Aron Brand, CTO of CTERA told CSOonline. "Additionally, the heightened sharing of sensitive information between parties provides more opportunities for data breaches." And "In the end, paying the ransom failed to protect UHG from secondary attempts at extortion." In April, cybercriminals from the RansomHub group threatened to leak portions of 6TB of sensitive data stolen from the breach of Change Healthcare, and obtained through Nichy, according to an analysis by security vendor Forescout. An estimated one in three Americans had their sensitive data exposed as a result of the attack. Such secondary scams are becoming increasingly commonplace and healthcare providers are particularly at risk, according to compliance experts... The US Department of Health and Human Services (HHS) is investigating whether a breach of protected health information occurred in assessing whether either UHG or Change Healthcare violated strict healthcare sector privacy regulations. Thanks to Slashdot reader snydeq for sharing the article.

Read more of this story at Slashdot.

IV infusion enables editing of the cystic fibrosis gene in lung stem cells

✇Ars Technica
By: John Timmer
13 June 2024 at 17:53
Abstract drawing of a pair of human hands using scissors to cut a DNA strand, with a number of human organs in the background.

Enlarge (credit: DrAfter123)

The development of gene editing tools, which enable the specific targeting and correction of mutations, hold the promise of allowing us to correct those mutations that cause genetic diseases. However, the technology has been around for a while now—two researchers were critical to its development in 2020—and there have been only a few cases where gene editing has been used to target diseases.

One of the reasons for that is the challenge of targeting specific cells in a living organism. Many genetic diseases affect only a specific cell type, such as red blood cells in sickle-cell anemia, or specific tissue. Ideally, to limit potential side effects, we'd like to ensure that enough of the editing takes place in the affected tissue to have an impact, while minimizing editing elsewhere to limit side effects. But our ability to do so has been limited. Plus, a lot of the cells affected by genetic diseases are mature and have stopped dividing. So, we either need to repeat the gene editing treatments indefinitely or find a way to target the stem cell population that produces the mature cells.

On Thursday, a US-based research team said that they've done gene editing experiments that targeted a high-profile genetic disease: cystic fibrosis. Their technique largely targets the tissue most affected by the disease (the lung), and occurs in the stem cell populations that produce mature lung cells, ensuring that the effect is stable.

Read 17 remaining paragraphs | Comments

New Report Underscores the Seriousness of Long Covid

✇NYT: Science
By: Pam Belluck
5 June 2024 at 12:22
The National Academies said the condition could involve up to 200 symptoms, make it difficult for people to work and last for months or years.

© Alex Wroblewski for The New York Times

Samantha Lewis, left, of Aurora, Ill., attending a physical therapy session to treat her long Covid symptoms in 2021.

Ancient Egyptian skull shows evidence of cancer, surgical treatment

✇Ars Technica
By: Jennifer Ouellette
5 June 2024 at 10:38
Skull and mandible 236, dating from between 2687 and 2345 BCE, belonged to a male individual aged 30 to 35.

Enlarge (credit: Tondini, Isidro, Camarós, 2024.)

The 4,000-year-old skull and mandible of an Egyptian man show signs of cancerous lesions and tool marks, according to a recent paper published in the journal Frontiers in Medicine. Those marks could be signs that someone tried to operate on the man shortly before his death or performed the ancient Egyptian equivalent of an autopsy to learn more about the cancer after death.

“This finding is unique evidence of how ancient Egyptian medicine would have tried to deal with or explore cancer more than 4,000 years ago,” said co-author Edgard Camarós, a paleopathologist at the University of Santiago de Compostela. “This is an extraordinary new perspective in our understanding of the history of medicine.”

Archaeologists have found evidence of various examples of primitive surgery dating back several thousand years. For instance, in 2022, archaeologists excavated a 5,300-year-old skull of an elderly woman (about 65 years old) from a Spanish tomb. They determined that seven cut marks near the left ear canal were strong evidence of a primitive surgical procedure to treat a middle ear infection. The team also identified a flint blade that may have been used as a cauterizing tool. By the 17th century, this was a fairly common procedure to treat acute ear infections, and skulls showing evidence of a mastoidectomy have been found in Croatia (11th century), Italy (18th and 19th centuries), and Copenhagen (19th or early 20th century).

Read 10 remaining paragraphs | Comments

FDA Reviews MDMA Therapy for PTSD, Citing Health Risks and Study Flaws

✇NYT: Science
By: Andrew Jacobs and Christina Jewett
1 June 2024 at 19:12
The agency’s staff analysis suggests that approval of the illegal drug known as Ecstasy for treatment of PTSD is far from certain, with advisers meeting next week to consider the proposed therapy.

© Noel Celis/Agence France-Presse — Getty Images

A seizure of the drug MDMA, known as Ecstasy or molly. It and other psychoactive drugs are still classified as illegal drugs with a potential for abuse.

The Textbooks Were Wrong About How Your Tongue Works

✇NYT: Science
By: Joanne Silberner
29 May 2024 at 11:08
The perception of taste is remarkably complex, not only on the tongue but in organs throughout the body.

© Alamy

The taste bud diagram, used in many textbooks over the years, originated in a 1901 study but was actually showing the sensitivity of different areas of the tongue.

CEO of Data Privacy Company Onerep.com Founded Dozens of People-Search Firms

✇Krebs on Security
By: BrianKrebs
14 March 2024 at 17:13

The data privacy company Onerep.com bills itself as a Virginia-based service for helping people remove their personal information from almost 200 people-search websites. However, an investigation into the history of onerep.com finds this company is operating out of Belarus and Cyprus, and that its founder has launched dozens of people-search services over the years.

Onerep’s “Protect” service starts at $8.33 per month for individuals and $15/mo for families, and promises to remove your personal information from nearly 200 people-search sites. Onerep also markets its service to companies seeking to offer their employees the ability to have their data continuously removed from people-search sites.

A testimonial on onerep.com.

Customer case studies published on onerep.com state that it struck a deal to offer the service to employees of Permanente Medicine, which represents the doctors within the health insurance giant Kaiser Permanente. Onerep also says it has made inroads among police departments in the United States.

But a review of Onerep’s domain registration records and that of its founder reveal a different side to this company. Onerep.com says its founder and CEO is Dimitri Shelest from Minsk, Belarus, as does Shelest’s profile on LinkedIn. Historic registration records indexed by DomainTools.com say Mr. Shelest was a registrant of onerep.com who used the email address dmitrcox2@gmail.com.

A search in the data breach tracking service Constella Intelligence for the name Dimitri Shelest brings up the email address dimitri.shelest@onerep.com. Constella also finds that Dimitri Shelest from Belarus used the email address d.sh@nuwber.com, and the Belarus phone number +375-292-702786.

Nuwber.com is a people search service whose employees all appear to be from Belarus, and it is one of dozens of people-search companies that Onerep claims to target with its data-removal service. Onerep.com’s website disavows any relationship to Nuwber.com, stating quite clearly, “Please note that OneRep is not associated with Nuwber.com.”

However, there is an abundance of evidence suggesting Mr. Shelest is in fact the founder of Nuwber. Constella found that Minsk telephone number (375-292-702786) has been used multiple times in connection with the email address dmitrcox@gmail.com. Recall that Onerep.com’s domain registration records in 2018 list the email address dmitrcox2@gmail.com.

It appears Mr. Shelest sought to reinvent his online identity in 2015 by adding a “2” to his email address. The Belarus phone number tied to Nuwber.com shows up in the domain records for comversus.com, and DomainTools says this domain is tied to both dmitrcox@gmail.com and dmitrcox2@gmail.com. Other domains that mention both email addresses in their WHOIS records include careon.me, docvsdoc.com, dotcomsvdot.com, namevname.com, okanyway.com and tapanyapp.com.

Onerep.com CEO and founder Dimitri Shelest, as pictured on the “about” page of onerep.com.

A search in DomainTools for the email address dmitrcox@gmail.com shows it is associated with the registration of at least 179 domain names, including dozens of mostly now-defunct people-search companies targeting citizens of Argentina, Brazil, Canada, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Latvia and Mexico, among others.

Those include nuwber.fr, a site registered in 2016 which was identical to the homepage of Nuwber.com at the time. DomainTools shows the same email and Belarus phone number are in historic registration records for nuwber.at, nuwber.ch, and nuwber.dk (all domains linked here are to their cached copies at archive.org, where available).

Nuwber.com, circa 2015. Image: Archive.org.

Update, March 21, 11:15 a.m. ET: Mr. Shelest has provided a lengthy response to the findings in this story. In summary, Shelest acknowledged maintaining an ownership stake in Nuwber, but said there was “zero cross-over or information-sharing with OneRep.” Mr. Shelest said any other old domains that may be found and associated with his name are no longer being operated by him.

“I get it,” Shelest wrote. “My affiliation with a people search business may look odd from the outside. In truth, if I hadn’t taken that initial path with a deep dive into how people search sites work, Onerep wouldn’t have the best tech and team in the space. Still, I now appreciate that we did not make this more clear in the past and I’m aiming to do better in the future.” The full statement is available here (PDF).

Original story:

Historic WHOIS records for onerep.com show it was registered for many years to a resident of Sioux Falls, SD for a completely unrelated site. But around Sept. 2015 the domain switched from the registrar GoDaddy.com to eNom, and the registration records were hidden behind privacy protection services. DomainTools indicates around this time onerep.com started using domain name servers from DNS provider constellix.com. Likewise, Nuwber.com first appeared in late 2015, was also registered through eNom, and also started using constellix.com for DNS at nearly the same time.

Listed on LinkedIn as a former product manager at OneRep.com between 2015 and 2018 is Dimitri Bukuyazau, who says their hometown is Warsaw, Poland. While this LinkedIn profile (linkedin.com/in/dzmitrybukuyazau) does not mention Nuwber, a search on this name in Google turns up a 2017 blog post from privacyduck.com, which laid out a number of reasons to support a conclusion that OneRep and Nuwber.com were the same company.

“Any people search profiles containing your Personally Identifiable Information that were on Nuwber.com were also mirrored identically on OneRep.com, down to the relatives’ names and address histories,” Privacyduck.com wrote. The post continued:

“Both sites offered the same immediate opt-out process. Both sites had the same generic contact and support structure. They were – and remain – the same company (even PissedConsumer.com advocates this fact: https://nuwber.pissedconsumer.com/nuwber-and-onerep-20160707878520.html).”

“Things changed in early 2016 when OneRep.com began offering privacy removal services right alongside their own open displays of your personal information. At this point when you found yourself on Nuwber.com OR OneRep.com, you would be provided with the option of opting-out your data on their site for free – but also be highly encouraged to pay them to remove it from a slew of other sites (and part of that payment was removing you from their own site, Nuwber.com, as a benefit of their service).”

Reached via LinkedIn, Mr. Bukuyazau declined to answer questions, such as whether he ever worked at Nuwber.com. However, Constella Intelligence finds two interesting email addresses for employees at nuwber.com: d.bu@nuwber.com, and d.bu+figure-eight.com@nuwber.com, which was registered under the name “Dzmitry.”

PrivacyDuck’s claims about how onerep.com appeared and behaved in the early days are not readily verifiable because the domain onerep.com has been completely excluded from the Wayback Machine at archive.org. The Wayback Machine will honor such requests if they come directly from the owner of the domain in question.

Still, Mr. Shelest’s name, phone number and email also appear in the domain registration records for a truly dizzying number of country-specific people-search services, including pplcrwlr.in, pplcrwlr.fr, pplcrwlr.dk, pplcrwlr.jp, peeepl.br.com, peeepl.in, peeepl.it and peeepl.co.uk.

The same details appear in the WHOIS registration records for the now-defunct people-search sites waatpp.de, waatp1.fr, azersab.com, and ahavoila.com, a people-search service for French citizens.

The German people-search site waatp.de.

A search on the email address dmitrcox@gmail.com suggests Mr. Shelest was previously involved in rather aggressive email marketing campaigns. In 2010, an anonymous source leaked to KrebsOnSecurity the financial and organizational records of Spamit, which at the time was easily the largest Russian-language pharmacy spam affiliate program in the world.

Spamit paid spammers a hefty commission every time someone bought male enhancement drugs from any of their spam-advertised websites. Mr. Shelest’s email address stood out because immediately after the Spamit database was leaked, KrebsOnSecurity searched all of the Spamit affiliate email addresses to determine if any of them corresponded to social media accounts at Facebook.com (at the time, Facebook allowed users to search profiles by email address).

That mapping, which was done mainly by generous graduate students at my alma mater George Mason University, revealed that dmitrcox@gmail.com was used by a Spamit affiliate, albeit not a very profitable one. That same Facebook profile for Mr. Shelest is still active, and it says he is married and living in Minsk [Update, Mar. 16: Mr. Shelest’s Facebook account is no longer active].

The Italian people-search website peeepl.it.

Scrolling down Mr. Shelest’s Facebook page to posts made more than ten years ago show him liking the Facebook profile pages for a large number of other people-search sites, including findita.com, findmedo.com, folkscan.com, huntize.com, ifindy.com, jupery.com, look2man.com, lookerun.com, manyp.com, peepull.com, perserch.com, persuer.com, pervent.com, piplenter.com, piplfind.com, piplscan.com, popopke.com, pplsorce.com, qimeo.com, scoutu2.com, search64.com, searchay.com, seekmi.com, selfabc.com, socsee.com, srching.com, toolooks.com, upearch.com, webmeek.com, and many country-code variations of viadin.ca (e.g. viadin.hk, viadin.com and viadin.de).

The people-search website popopke.com.

Domaintools.com finds that all of the domains mentioned in the last paragraph were registered to the email address dmitrcox@gmail.com.

Mr. Shelest has not responded to multiple requests for comment. KrebsOnSecurity also sought comment from onerep.com, which likewise has not responded to inquiries about its founder’s many apparent conflicts of interest. In any event, these practices would seem to contradict the goal Onerep has stated on its site: “We believe that no one should compromise personal online security and get a profit from it.”

The people-search website findmedo.com.

Max Anderson is chief growth officer at 360 Privacy, a legitimate privacy company that works to keep its clients’ data off of more than 400 data broker and people-search sites. Anderson said it is concerning to see a direct link between between a data removal service and data broker websites.

“I would consider it unethical to run a company that sells people’s information, and then charge those same people to have their information removed,” Anderson said.

Last week, KrebsOnSecurity published an analysis of the people-search data broker giant Radaris, whose consumer profiles are deep enough to rival those of far more guarded data broker resources available to U.S. police departments and other law enforcement personnel.

That story revealed that the co-founders of Radaris are two native Russian brothers who operate multiple Russian-language dating services and affiliate programs. It also appears many of the Radaris founders’ businesses have ties to a California marketing firm that works with a Russian state-run media conglomerate currently sanctioned by the U.S. government.

KrebsOnSecurity will continue investigating the history of various consumer data brokers and people-search providers. If any readers have inside knowledge of this industry or key players within it, please consider reaching out to krebsonsecurity at gmail.com.

Update, March 15, 11:35 a.m. ET: Many readers have pointed out something that was somehow overlooked amid all this research: The Mozilla Foundation, the company that runs the Firefox Web browser, has launched a data removal service called Mozilla Monitor that bundles OneRep. That notice says Mozilla Monitor is offered as a free or paid subscription service.

“The free data breach notification service is a partnership with Have I Been Pwned (“HIBP”),” the Mozilla Foundation explains. “The automated data deletion service is a partnership with OneRep to remove personal information published on publicly available online directories and other aggregators of information about individuals (“Data Broker Sites”).”

In a statement shared with KrebsOnSecurity.com, Mozilla said they did assess OneRep’s data removal service to confirm it acts according to privacy principles advocated at Mozilla.

“We were aware of the past affiliations with the entities named in the article and were assured they had ended prior to our work together,” the statement reads. “We’re now looking into this further. We will always put the privacy and security of our customers first and will provide updates as needed.”

❌
❌